Form 4: Brainstorm Cell Therapeutics CEO Increases Stake in Company

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through multiple transactions.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, has reported changes in his beneficial ownership of the company's stock.
• On April 17, 2024, Lebovits acquired 130,000 shares of common stock at a weighted average price of $0.5457.
• On April 18, 2024, he acquired another 115,072 shares at a weighted average price of $0.5255.
• Following these transactions, Lebovits directly owns 843,565 shares of common stock.
• He may also be deemed the beneficial owner of 2,000,847 shares held by ACCBT Corp. and ACC International Holdings Ltd.

Sentiment

Score: 7

Explanation: The CEO increasing his stake in the company is generally a positive sign, suggesting confidence in the company's future. However, it's just one data point and needs to be considered alongside other factors.

Positives

• The CEO's increased investment in the company may signal confidence in Brainstorm Cell Therapeutics' future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like CEOs, buy or sell their company's stock. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the CEO's increased stock ownership as a positive signal.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock, Beneficial Ownership, SEC Form 4